



Pharmaceuticals – Pipeline Overview¹ (as of October 30, 2025)

Phase I		
VVD KEAP1 Act (VVD-130037 aka NRF2 Inh, BAY 3605349)		
225Ac-Pelgifatamab (BAY 3546828)		
225Ac-PSMA-Trillium (BAY 3563254)		
SOS1 Inhibitor (BAY 3498264)		
PRMT5 Inhibitor (BAY 3713372)		
VVD RAS-PI3K Inhibitor (VVD-159642, BAY 3674171)		
225Ac-GPC3 (BAY 3547926)		
VVD WRN Inhibitor (VVD-214)		
KRAS G12D Inhibitor (BAY 3771249)		
SEMA 3a (BAY 3401016)		
Dual FIIa/Xa Inhibitor (BAY 3389934)		
GIRK4 Inhibitor (BAY 3670549)		
Multiple System Atrophy rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-MSA)		
Pompe Disease rAAV Gene Therapy (ACTUS-101)		
LGMD2I/R9 rAAV Gene Therapy (AB-1003 aka LION-101)		
GPR84 Antagonist (BAY 3178275)		
BAY 2701250		
Primary Photoreceptor Diseases Cell Therapy (BRT-OpCT-001)		

Phase II		
Sevabertinib (HER2/mEGFR Inhibitor) (BAY 2927088)		
// Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)		
Congestive Heart Failure rAAV Gene Therapy (AB-1002)		
// Congestive Heart Failure (GenePHIT)		
Anti-a2AP (BAY 3018250)		
// Acute Ischemic Stroke; Pulmonary Embolism (SIRIUS)		
Nurandociguat (sGC Activator Oral) (BAY 3283142)		
// Chronic Kidney Disease (ALPINE-1)		
Parkinson's Disease rAAV Gene Therapy (AB-1005)		
// Parkinson's Disease (REGENERATE-PD)		

Phase III		
Darolutamide (AR Inhibitor)		
// Adjuvant Prostate Cancer (DASL-HiCaP)		
// Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)		
Sevabertinib (HER2/mEGFR Inhibitor)		
// Advanced Non-small Cell Lung Cancer with HER2 Activating Mutations, 1L (SOHO-02)		
Finerenone (MR Antagonist)		
// Non-diabetic Chronic Kidney Disease (FIND-CKD)		
// Chronic Kidney Disease in Type 1 Diabetes (FINE-ONE)		
Vericiguat (sGC Stimulator)		
// Heart Failure (HFrEF) (VICTOR ²)		
Asundexian (FXIa Inhibitor)		
// 2 ^o Stroke Prevention (OCEANIC-STROKE)		
Bemdaneprocel (Cell Therapy)		
// Parkinson's Disease (exPDite-2)		

Submissions		
Darolutamide (AR Inhibitor)		
// CN: Prostate Cancer (mHSPC)		
Sevabertinib (HER2/mEGFR Inhibitor)		
// CN, US, JP: HER2-mut NSCLC 2L		
Finerenone (MR Antagonist)		
// EU, CN, JP: Heart Failure (HFrEF/pEF)		
Elinzanetant (Neurokinin-1,3 Rec Antagonist)		
// EU: Vasomotor Symptoms		
Aflibercept 8mg (VEGF-Inhibitor)		
// EU, JP, CN: Retinal Vein Occlusion		
Gadoquatrane (High Relaxivity Contrast Agent)		
// US, EU, JP, CN: Magnetic Resonance Imaging		

	Oncology
	Cardiovascular+ ³
	Neurology & Rare Diseases
	Immunology
	Others
	New molecular entity
	Life cycle management

Protein Therapeutics Cell Therapy Contrast Agent Genetic Medicine Radionuclide Therapy Small Molecule

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit
² Conducted by Merck & Co ³ Including Precision Cardiovascular, Nephrology & Acute Care